Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 48

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 48
---
 consideration: • stage of development, • growth in revenue, and • stock price In general, the People & Compensation Committee accords less weight to market capitalization due in part to the number of factors that can influence and cause volatility in the trading price of the common stock of a company. In addition, the People & Compensation Committee views the consistency and robustness of the peer group over time as being very important. At the time the 2024 peer group was approved by the People & Compensation Committee in September 2023, based on analysis and recommendations from Aon, our market capitalization was positioned at approximately the 28 th percentile of our peer group, and our projected 2023 year-ending revenues was positioned at approximately the 69 th percentile of our peer group. Other factors considered to a lesser extent were as follows: (i) headcount, where we were positioned at the 52 nd percentile of the approved peer group, (ii) 3-year revenue growth, where we were positioned at the 55 th percentile, and (iii) 3-year relative total stockholder return (TSR), where we were positioned at the 28 th percentile. The People & Compensation Committee believes that the companies selected to our peer group are broadly comparable to us and represent our labor market for talent for key leadership positions. Our People & Compensation Committee annually reviews our peer group with Aon to determine if adjustments are necessary to ensure that it continues to be relevant or if additional peer companies or groups are necessary to provide appropriate information on market practices and compensation levels. Where possible, the People & Compensation Committee prefers to maintain consistency in the peer group year-over-year and takes into consideration our future outlook and growth strategy in relation to companies proposed for inclusion or exclusion from the current peer group. Pacira BioSciences, Inc. 2025 Proxy Statement | 61

TABLE OF CONTENTS Executive Compensation

Our peer group for 2024 compensation purposes was as follows:

| Company Name                    | ​ | ​ | Ticker 
 Symbol | ​ | ​ |   |   |         | Trailing 12-MonthRevenue as ofAugust 4, 2023($ miillions) | ​ | ​ |   |   |      | 30-Day AverageMarket Cap as ofAugust 4, 2023($ billions) | ​ |
|:--------------------------------|:--|:--|:-------|:--|:--|:--|:--|--------:|:----------------------------------------------------------|:--|:--|:--|